Renal angiomyolipoma-patient characteristics and treatment with focus on active surveillance

Figures & data

Table 1. Characteristics of all AML-patients.

	All	Sporadic	TSC
Patients, n	98	87	11
Sex (F/M)	80/18	72/15	8/3
Age at diagnosis, median (range)	54 (13–89)	56 (26–89)	24 (13–41)
Clinical presentation, n:
Incidental/Symptomatic	60/38	56/31	4/7
Intervention, n, yes/no	64/34	53/34	11/0
Size of lesion, mm, mean (range)	51 (5–300)	46 (5–200)	105 (50–300)
Laterality of lesion, n, (%)
L	40 (41)	39 (45)	1 (9)
R	42 (43)	42 (48)	0
B	16 (16)	6 (7)	10 (91)
Lesions per patient, n, (%)
1	73 (74)	72 (83)	1 (9)
2	7 (7)	6 (7)	1 (9)
3	2 (2)	2 (2)	0
>4	16 (16)	7 (8)	9 (82)
Follow-up, months, median (range)	54 (0–308)^a	51 (0–308)^a	76 (22–248)

L: left; R: right; B: bilateral.

^aThree patients who refused follow-up are not included.

Figure 1. Twenty years old woman with tuberous sclerosis. Multifocal and bilateral angiomyolipoma with largest lesion of 60 mm. Initially followed with active surveillance but after five years intervention with angioembolization due to increasing size.

Figure 2. Fifty years old woman with 40 mm sporadic angiomyolipoma followed with active surveillance. Six mm increase in size in seven years.

Figure 3. Flow-chart of the patients up to the first treatment. Number of TSC-patients specified within brackets.

Table 2. Characteristics of patients in active surveillance.

	All	Sporadic	TSC
Patients, n	51	45	6
Sex (F/M)	43/8	39/6	4/2
Age at diagnosis, median (range)	51 (14–85)	55 (26–85)	21 (14–33)
Clinical presentation, n:
Incidental/Symptomatic	42/9	37/8	5/1
Intervention, n, yes/no	18/51	12/33	6/0
Size of lesion, m mean (range)	43 (5–300)	34 (5–100)	120 (50–300)
Laterality of lesion, n (%)
L	23 (45)	23 (51)	0 (0)
R	19 (37)	19 (42)	0 (0)
B	9 (18)	3 (7)	6 (100)
Lesions per patient, n (%)
1	37 (73)	37 (82)	0 (0)
2	4 (8)	3 (7)	1 (17)
3	1 (2)	1 (2)	0 (0)
>4	9 (18)	4 (9)	5 (83)
Bleeding during follow-up, n, yes/no	3/45	1/42	2/6
Follow-up, months, mean (range)	72 (3–308)^a	67 (3–308)^a	109 (23–248)

^aThree patients who refused follow-up are not included.